Regulation of PD-L1 expression in the tumor microenvironment

被引:411
作者
Yi, Ming [1 ]
Niu, Mengke [1 ,2 ,3 ]
Xu, Linping [2 ,3 ]
Luo, Suxia [2 ,3 ]
Wu, Kongming [1 ,2 ,3 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Oncol, Tongji Hosp, Wuhan 430030, Peoples R China
[2] Zhengzhou Univ, Dept Med Oncol, Affiliated Canc Hosp, Zhengzhou 450008, Peoples R China
[3] Henan Canc Hosp, Zhengzhou 450008, Peoples R China
基金
中国国家自然科学基金;
关键词
Cancer immunology; PD-L1; PD-1; Transcriptional regulation; Post-transcriptional modification; PROMOTES ANTITUMOR IMMUNITY; SQUAMOUS-CELL CARCINOMA; PD-LL EXPRESSION; NF-KAPPA-B; LUNG-CANCER; UP-REGULATION; TNF-ALPHA; TGF-BETA; SIGNALING PATHWAYS; DENDRITIC CELLS;
D O I
10.1186/s13045-020-01027-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Programmed death-ligand 1 (PD-L1) on cancer cells engages with programmed cell death-1 (PD-1) on immune cells, contributing to cancer immune escape. For multiple cancer types, the PD-1/PD-L1 axis is the major speed-limiting step of the anti-cancer immune response. In this context, blocking PD-1/PD-L1 could restore T cells from exhausted status and eradicate cancer cells. However, only a subset of PD-L1 positive patients benefits from alpha-PD-1/PD-L1 therapies. Actually, PD-L1 expression is regulated by various factors, leading to the diverse significances of PD-L1 positivity. Understanding the mechanisms of PD-L1 regulation is helpful to select patients and enhance the treatment effect. In this review, we focused on PD-L1 regulators at the levels of transcription, post-transcription, post-translation. Besides, we discussed the potential applications of these laboratory findings in the clinic.
引用
收藏
页数:13
相关论文
共 153 条
  • [1] MET Receptor Tyrosine Kinase Regulates the Expression of Co-Stimulatory and Co-Inhibitory Molecules in Tumor Cells and Contributes to PD-L1-Mediated Suppression of Immune Cell Function
    Ahn, Hyun Kyung
    Kim, Sehui
    Kwon, Dohee
    Koh, Jaemoon
    Kim, Young A.
    Kim, Kwangsoo
    Chung, Doo Hyun
    Jeon, Yoon Kyung
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (17)
  • [2] Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
    Akbay, Esra A.
    Koyama, Shohei
    Carretero, Julian
    Altabef, Abigail
    Tchaicha, Jeremy H.
    Christensen, Camilla L.
    Mikse, Oliver R.
    Cherniack, Andrew D.
    Beauchamp, Ellen M.
    Pugh, Trevor J.
    Wilkerson, Matthew D.
    Fecci, Peter E.
    Butaney, Mohit
    Reibel, Jacob B.
    Soucheray, Margaret
    Cohoon, Travis J.
    Janne, Pasi A.
    Meyerson, Matthew
    Hayes, D. Neil
    Shapiro, Geoffrey I.
    Shimamura, Takeshi
    Sholl, Lynette M.
    Rodig, Scott J.
    Freeman, Gordon J.
    Hammerman, Peter S.
    Dranoff, Glenn
    Wong, Kwok-Kin
    [J]. CANCER DISCOVERY, 2013, 3 (12) : 1355 - 1363
  • [3] Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
    Akinleye, Akintunde
    Rasool, Zoaib
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (01)
  • [4] Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy
    Al Emran, Abdullah
    Chatterjee, Aniruddha
    Rodger, Euan J.
    Tiffen, Jessamy C.
    Gallagher, Stuart J.
    Eccles, Michael R.
    Hersey, Peter
    [J]. TRENDS IN IMMUNOLOGY, 2019, 40 (04) : 328 - 344
  • [5] Albitar Maher, 2018, Oncotarget, V9, P13682, DOI 10.18632/oncotarget.24455
  • [6] Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas
    Anastasiadou, Eleni
    Stroopinsky, Dina
    Alimperti, Stella
    Jiao, Alan L.
    Pyzer, Athalia R.
    Cippitelli, Claudia
    Pepe, Giuseppina
    Severa, Martina
    Rosenblatt, Jacalyn
    Etna, Marilena P.
    Rieger, Simone
    Kempkes, Bettina
    Coccia, Eliana M.
    Sui, Shannan J. Ho
    Chen, Christopher S.
    Uccini, Stefania
    Avigan, David
    Faggioni, Alberto
    Trivedi, Pankaj
    Slack, Frank J.
    [J]. LEUKEMIA, 2019, 33 (01) : 132 - 147
  • [7] PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
    Ansell, Stephen M.
    Lesokhin, Alexander M.
    Borrello, Ivan
    Halwani, Ahmad
    Scott, Emma C.
    Gutierrez, Martin
    Schuster, Stephen J.
    Millenson, Michael M.
    Cattry, Deepika
    Freeman, Gordon J.
    Rodig, Scott J.
    Chapuy, Bjoern
    Ligon, Azra H.
    Zhu, Lili
    Grosso, Joseph F.
    Kim, Su Young
    Timmerman, John M.
    Shipp, Margaret A.
    Armand, Philippe
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) : 311 - 319
  • [8] PD-L1 expression is regulated by both DNA methylation and NF-κB during EMT signaling in non-small cell lung carcinoma
    Asgarova, A.
    Asgarov, K.
    Godet, Y.
    Peixoto, P.
    Nadaradjane, A.
    Boyer-Guittaut, M.
    Galaine, J.
    Guenat, D.
    Mougey, V.
    Perrard, J.
    Pallandre, J. R.
    Bouard, A.
    Balland, J.
    Tirole, C.
    Adotevi, O.
    Hendrick, E.
    Herfs, M.
    Cartron, P. F.
    Borg, C.
    Hervouet, E.
    [J]. ONCOIMMUNOLOGY, 2018, 7 (05):
  • [9] miRNA-148a-3p Regulates Immunosuppression in DNA Mismatch Repair-Deficient Colorectal Cancer by Targeting PD-L1
    Ashizawa, Mai
    Okayama, Hirokazu
    Ishigame, Teruhide
    Min, Aung Kyi Thar
    Saito, Katsuharu
    Ujiie, Daisuke
    Murakami, Yuko
    Kikuchi, Tomohiro
    Nakayama, Yuko
    Noda, Masaru
    Tada, Takeshi
    Endo, Hisahito
    Fujita, Shotaro
    Sakamoto, Wataru
    Saito, Motonobu
    Saze, Zenichiro
    Momma, Tomoyuki
    Ohki, Shinji
    Mimura, Kosaku
    Kono, Koji
    [J]. MOLECULAR CANCER RESEARCH, 2019, 17 (06) : 1403 - 1413
  • [10] Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
    Atefi, Mohammad
    Avramis, Earl
    Lassen, Amanda
    Wong, Deborah J. L.
    Robert, Lidia
    Foulad, David
    Cerniglia, Michael
    Titz, Bjoern
    Chodon, Thinle
    Graeber, Thomas G.
    Comin-Anduix, Begonya
    Ribas, Antoni
    [J]. CLINICAL CANCER RESEARCH, 2014, 20 (13) : 3446 - 3457